Here's an uncomfortable truth about clinical research: it's expensive, it takes years, and if someone pulls the plug halfway through, you've got a serious problem. That's exactly what happened when the National Institutes of Health started terminating research grants in early 2025, shortly after President Trump took office.

A new cross-sectional study has quantified the damage, and the numbers are sobering. Between February 28 and August 15, 2025, nearly 1 in 30 NIH-funded clinical trials lost their financial backing. That might not sound catastrophic until you realize what it means in human terms: more than 74,000 people enrolled in active trials suddenly found themselves in studies that couldn't continue as planned.

The researchers used the NIH ExPORTER database to track 11,008 clinical trials that had active grants as of February 28, 2025, the date the first termination appeared. By mid-August, 383 of those trials had their grants terminated.

Clinical trials aren't exactly something you can pause and restart like a Netflix subscription. They require sustained financial support to maintain safety protocols, follow participants, and collect meaningful data. When funding vanishes unexpectedly, it creates a cascade of problems involving data integrity, financial waste, and ethical obligations to the people who volunteered for these studies.

The 74,311 individuals most directly affected were enrolled in trials classified as "active and not recruiting" at the moment funding was cut. Translation: these weren't theoretical future studies. These were ongoing interventions, possibly with people receiving treatments or undergoing procedures that now faced disruption.

Interestingly, the funding cuts weren't distributed evenly. Larger, more ambitious trials took a disproportionate hit. The median anticipated enrollment for terminated trials was 105 participants, compared to 72 for trials that kept their funding. Bigger studies, bigger targets, apparently.

The research area also mattered considerably. Infectious disease trials faced the steepest cuts, with 14.4% experiencing grant termination. Prevention and behavioral intervention studies were also hit harder than average. Meanwhile, neurological and reproductive health trials saw the lowest termination rates at just 2.2%.

Geography played a role too. International trials were significantly more vulnerable, with 5.8% losing funding compared to 3.4% for U.S.-based research. Within the United States, the Northeast saw disproportionate impacts.

When broken down by trial phase, phase 1 trials experienced the highest termination rate at 3.7%, while phase 2-3 trials saw no terminations at all. Among the 383 affected trials, 36.1% had already been completed when funding was pulled. But here's the kicker: 34.5% were actively recruiting new participants when the money stopped flowing.

The study authors acknowledged some limitations, including their reliance on investigator-reported data and the lack of comprehensive historical data on grant terminations before 2025, making it difficult to compare this surge to previous patterns.

What we're left with is a snapshot of what happens when research funding becomes unpredictable. The financial waste is one thing, but the ethical complications of disrupting trials with tens of thousands of enrolled participants adds a whole different dimension to the conversation about government research priorities.